Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194271 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Ipilimumab in Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01194271: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01194271 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01194271, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how ipilimumab in combination with Lupron (leuprolide acetate) affects the body's own defense (immune) system before having surgery to remove prostate cancer. The safety of the drug combination will also be studied.
Interventions
- DRUG Ipilimumab
- PROCEDURE Radical Prostatectomy
- DRUG Leuprolide Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194271
The ClinicalTrials.gov registry entry for NCT01194271 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ipilimumab is the first listed.
NCT01194271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194271 about?
NCT01194271 is a clinical study titled "Neoadjuvant Ipilimumab in Prostate Cancer". The goal of this clinical research study is to learn how ipilimumab in combination with Lupron (leuprolide acetate) affects the body's own defense (immune) system before having surgery to remove prostate cancer. The safety of the drug combination will also be studied.
What is the current status of trial NCT01194271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2010-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01194271?
The interventions under investigation include: Ipilimumab (DRUG), Radical Prostatectomy (PROCEDURE), Leuprolide Acetate (DRUG).
Who is sponsoring clinical trial NCT01194271?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.